BrightEdge - American Cancer Society

Cerula Care specializes in behavioral health services for individuals with chronic conditions. It offers virtual care through care management, coaching, psychiatry, focusing on managing anxiety, depression, substance use disorder, and post-traumatic stress disorder.

TippingPoint Biosciences is developing therapeutics that target abnormal DNA packaging states in diseases such as cancer.

SyzOnc is a biotechnology company focused on developing therapies for solid tumors with few effective options. It uses AI, the Cell Painting assay, and cell-based models of the tumor microenvironment to identify multi-modal cancer targets and lead compounds. The platform integrates machine learning, imaging-based phenomics, and specialized bioassays to model multiple cancer types and address cancer cell proliferation, extracellular matrix regulation, and immune evasion. The initial focus targets the Hippo pathway, an underexploited cancer pathway linked to soft-tissue sarcoma, influencing tumor growth, matrix deposition, and T cell function. The company builds proprietary tumor ecosystem models from public and private data to compare genetic and compound phenotypes and generate starting points for drug development. Founders include experts from Broad Institute and UPenn, and the company has established a laboratory space in Philadelphia to advance its platform and programs.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.